These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2867823)

  • 41. The metabolic effects of chronic hyperglucagonaemia.
    Nankervis A; Proietto J; Ng KW; Alford FP; Larkins R
    Clin Endocrinol (Oxf); 1981 Oct; 15(4):325-33. PubMed ID: 6274544
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Familial hyperglucagonemia--an autosomal dominant disorder.
    Boden G; Owen OE
    N Engl J Med; 1977 Mar; 296(10):534-8. PubMed ID: 189188
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Glucagonoma without the glucagonoma syndrome].
    Morosini M; Sommo M; Marconi R
    Minerva Chir; 1985 May; 40(10):707-9. PubMed ID: 2993957
    [No Abstract]   [Full Text] [Related]  

  • 44. Cystic glucagonoma with loss of heterozygosity on chromosome 11 in multiple endocrine neoplasia type 1.
    Sarui H; Yoshimoto K; Okumura S; Kamura M; Takuno H; Ishizuka T; Takao H; Shimokawa K; Itakura M; Saji S; Yasuda K
    Clin Endocrinol (Oxf); 1997 Apr; 46(4):511-6. PubMed ID: 9196616
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glucagonoma syndrome and necrolytic migratory erythema.
    Lobo I; Carvalho A; Amaral C; Machado S; Carvalho R
    Int J Dermatol; 2010 Jan; 49(1):24-9. PubMed ID: 20465606
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The long-acting somatostatin analogue octreotide alleviates symptoms by reducing posttranslational conversion of prepro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth.
    Jockenhövel F; Lederbogen S; Olbricht T; Schmidt-Gayk H; Krenning EP; Lamberts SW; Reinwein D
    Clin Investig; 1994 Jan; 72(2):127-33. PubMed ID: 8186658
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gastrointestinal/pancreatic hormone concentrations in the portal venous system of nine patients with organic hyperinsulinism.
    Glaser B; Valtysson G; Fajans SS; Vinik AI; Cho K; Thompson N
    Metabolism; 1981 Oct; 30(10):1001-10. PubMed ID: 6116152
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Extrapancreatic glucagon in control of glucose turnover in depancreatized dogs.
    Ross G; Lickley L; Vranic M
    Am J Physiol; 1978 Feb; 234(2):E213-19. PubMed ID: 623297
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rare presentation of endocrine pancreatic tumor: a case of diffuse glucagonoma without metastasis and necrolytic migratory erythema.
    Chen HW; Chen HW; Su DH; Shun CT; Liu KL
    J Formos Med Assoc; 2005 May; 104(5):363-6. PubMed ID: 15959605
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The glucagon syndrome].
    Goldinger G; Aeberhard P
    Helv Chir Acta; 1980 Jun; 47(1-2):199-204. PubMed ID: 6254912
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Amino acid deficiency and the skin rash associated with glucagonoma.
    Norton JA; Kahn CR; Schiebinger R; Gorschboth C; Brennan MF
    Ann Intern Med; 1979 Aug; 91(2):213-5. PubMed ID: 111595
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rapid resolution of necrolytic migratory erythema after glucagonoma resection.
    Smith AP; Doolas A; Staren ED
    J Surg Oncol; 1996 Apr; 61(4):306-9. PubMed ID: 8628004
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modulatory effect of glucose, amino acids, and secretin on CCK-8-induced somatostatin and pancreatic polypeptide release in dogs.
    Schusdziarra V; Lenz N; Schick R; Maier V
    Diabetes; 1986 May; 35(5):523-9. PubMed ID: 2869995
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Glucagonoma syndrome.
    Hashizume T; Kiryu H; Noda K; Kano T; Nakano R
    J Am Acad Dermatol; 1988 Aug; 19(2 Pt 2):377-83. PubMed ID: 2842381
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The glucagonoma syndrome.
    Shupack JL; Berczeller PH; Stevens DM
    J Dermatol Surg Oncol; 1978 Mar; 4(3):242-7. PubMed ID: 204668
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Response of glucagonomas to surgical excision and chemotherapy. Report of two cases and review of the literature.
    Reyes-Govea J; Holm A; Aldrete JS
    Am Surg; 1989 Aug; 55(8):523-7. PubMed ID: 2548427
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Necrolytic Migratory Erythema: Complete Healing after Surgical Removal of Pancreatic Carcinoma.
    V'lckova-Laskoska M; Balabanova-Stefanova M; Arsovska-Bezhoska I; Caca-Biljanovska N; Laskoski D
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):329-332. PubMed ID: 30665484
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunological studies in a patient with the glucagonoma syndrome.
    Dohlsten M; Hallberg T
    Acta Med Scand; 1985; 218(2):251-5. PubMed ID: 2998160
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dermatitis, glossitis, stomatitis, cheilitis, anemia and weight loss: a classic presentation of pancreatic glucagonoma.
    Povoski SP; Zaman SA; Ducatman BS; McFadden DW
    W V Med J; 2002; 98(1):12-4. PubMed ID: 11941895
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995.
    Boden G; Ryan IG; Eisenschmid BL; Shelmet JJ; Owen OE
    N Engl J Med; 1986 Jun; 314(26):1686-9. PubMed ID: 2872592
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.